Physiological replacement of T3 improves left ventricular function in an animal model of myocardial infarction-induced congestive heart failure

Circulation: Heart Failure

Volumn 2, Issue 3, 2009, Pages 243-252

  Henderson, Kyle K ^a   Danzi, Sara ^b   Paul, Jennifer T ^a   Leya, Greg ^a   Klein, Irwin ^b   Samarel, Allen M ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

Heart failure; Low T3 syndrome; Myocardial infarction; Thyroid

Indexed keywords

MYOSIN HEAVY CHAIN ALPHA; MYOSIN HEAVY CHAIN BETA; LIOTHYRONINE; MESSENGER RNA; MYOSIN HEAVY CHAIN; VENTRICULAR MYOSIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DIASTOLIC BLOOD PRESSURE; DRESSLER SYNDROME; GENE EXPRESSION; HEART ARRHYTHMIA; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART RATE; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ANIMAL; BLOOD; BLOOD PRESSURE; CONVALESCENCE; DIASTOLE; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; HEART CONTRACTION; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HORMONE SUBSTITUTION; INFUSION PUMP; METABOLISM; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; SYSTOLE; TIME;

ANIMALS; BLOOD PRESSURE; DIASTOLE; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HEART FAILURE; HEART RATE; HORMONE REPLACEMENT THERAPY; HYPERTROPHY, LEFT VENTRICULAR; INFUSION PUMPS, IMPLANTABLE; MALE; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; MYOSIN HEAVY CHAINS; RATS; RATS, SPRAGUE-DAWLEY; RECOVERY OF FUNCTION; RNA, MESSENGER; SYSTOLE; TIME FACTORS; TRIIODOTHYRONINE; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR MYOSINS;

EID: 70350457660     PISSN: 19413289     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.108.810747     Document Type: Article

References (48)

1. Brent GA. The molecular basis of thyroid hormone action. N Engl J Med. 1994; 331:847- 853.
2. Klein I, Danzi S. Thyroid disease and the heart. Circulation. 2007; 116: 1725-1735.
3. Morkin E, Flink IL, Goldman S. Biochemical and physiologic effects of thyroid hormone on cardiac performance. Prog Cardiovasc Dis. 1983; 25:435-464.
4. Bilezikian JP, Loeb JN. The influence of hyperthyroidism and hypothyroidism on alpha- and beta-adrenergic receptor systems and adrenergic responsiveness. Endocr Rev. 1983; 4:378 -388.
5. Rohrer D, Dillmann WH. Thyroid hormone markedly increases the mRNA coding for sarcoplasmic reticulum Ca2+-ATPase in the rat heart. J Biol Chem. 1988; 263:6941- 6944.
6. Nishiyama A, Kambe F, Kamiya K, Yamaguchi S, Murata Y, Seo H, Toyama J. Effects of thyroid and glucocorticoid hormones on Kv1.5 potassium channel gene expression in the rat left ventricle. Biochem Biophys Res Commun. 1997; 237:521-526.
7. Ladenson PW, Bloch KD, Seidman JG. Modulation of atrial natriuretic factor by thyroid hormone: messenger ribonucleic acid and peptide levels in hypothyroid, euthyroid, and hyperthyroid rat atria and ventricles. Endocrinology. 1988; 123:652- 657.
8. Awais D, Shao Y, Ismail-Beigi F. Thyroid hormone regulation of myocardial Na/K-ATPase gene expression. J Mol Cell Cardiol. 2000; 32: 1969-1980.
9. Gustafson TA, Markham BE, Morkin E. Effects of thyroid hormone on alpha-actin and myosin heavy chain gene expression in cardiac and skeletal muscles of the rat: measurement of mRNA content using synthetic oligonucleotide probes. Circ Res. 1986;59:194-201.
10. Lompre AM, Nadal-Ginard B, Mahdavi V. Expression of the cardiac ventricular alpha- and beta-myosin heavy chain genes is developmentally and hormonally regulated. J Biol Chem. 1984; 259:6437- 6446.
11. Kinugawa K, Yonekura K, Ribeiro RC, Eto Y, Aoyagi T, Baxter JD, Camacho SA, Bristow MR, Long CS, Simpson PC. Regulation of thyroid hormone receptor isoforms in physiological and pathological cardiac hypertrophy. Circ Res. 2001; 89:591-598.
12. Boerth SR, Artman M. Thyroid hormone regulates Na(+)-Ca2+ exchanger expression during postnatal maturation and in adult rabbit ventricular myocardium. Cardiovasc Res. 1996; 31 Spec No:E145-E152.
13. Kiss E, Jakab G, Kranias EG, Edes I. Thyroid hormone-induced alterations in phospholamban protein expression. Regulatory effects on sarcoplasmic reticulum Ca2- transport and myocardial relaxation. Circ Res. 1994; 75:245-251.
14. Katzeff HL, Powell SR, Ojamaa K. Alterations in cardiac contractility and gene expression during low-T3 syndrome: prevention with T3. Am J Physiol. 1997; 273:E951-E956.
15. Hamilton MA, Stevenson LW, Luu M, Walden JA. Altered thyroid hormone metabolism in advanced heart failure. J Am Coll Cardiol. 1990; 16:91-95.
16. Hamilton MA, Stevenson LW, Fonarow GC, Steimle A, Goldhaber JI, Child JS, Chopra IJ, Moriguchi JD, Hage A. Safety and hemodynamic effects of intravenous triiodothyronine in advanced congestive heart failure. Am J Cardiol. 1998; 81:443- 447.
17. Klein I, Danzi S. Thyroid hormone treatment to mend a broken heart. J Clin Endocrinol Metab. 2008; 93:1172-1174.
18. Pingitore A, Galli E, Barison A, Iervasi A, Scarlattini M, Nucci D, L'Abbate A, Mariotti R, Iervasi G. Acute Effects of triiodothyronine replacement therapy in patients with chronic heart failure and low-t3 syndrome: a randomized, placebo-controlled study. J Clin Endocrinol Metab. 2008; 93:1351-1358.
19. Morkin E, Pennock GD, Raya TE, Bahl JJ, Goldman S. Studies on the use of thyroid hormone and a thyroid hormone analogue in the treatment of congestive heart failure. Ann Thorac Surg. 1993; 56:S54 -S60.
20. Ojamaa K, Kenessey A, Shenoy R, Klein I. Thyroid hormone metabolism and cardiac gene expression after acute myocardial infarction in the rat. Am J Physiol Endocrinol Metab. 2000; 279:E1319-E1324.
21. Gay RG, Graham S, Aguirre M, Goldman S, Morkin E. Effects of 10- to 12-day treatment with L-thyroxine in rats with myocardial infarction. Am J Physiol. 1988; 255:H801-H806.
22. Musch TI, Terrell JA. Skeletal muscle blood flow abnormalities in rats with a chronic myocardial infarction: rest and exercise. Am J Physiol. 1992; 262:H411-H419.
23. Pfeffer MA, Pfeffer JM, Fishbein MC, Fletcher PJ, Spadaro J, Kloner RA, Braunwald E. Myocardial infarct size and ventricular function in rats. Circ Res. 1979; 44:503-512.
24. Henze M, Hart D, Samarel A, Barakat J, Eckert L, Scrogin K. Persistent alterations in heart rate variability, baroreflex sensitivity, and anxiety-like behaviors during development of heart failure in the rat. Am J Physiol Heart Circ Physiol. 2008; 295:H29-H38.
25. Hart DL, Heidkamp MC, Iyengar R, Vijayan K, Szotek EL, Barakat JA, Leya M, Henze M, Scrogin K, Henderson KK, Samarel AM. CRNK gene transfer improves function and reverses the myosin heavy chain isoenzyme switch during post-myocardial infarction left ventricular remodeling. J Mol Cell Cardiol. 2008; 45:93-105.
26. Balkman C, Ojamaa K, Klein I. Time course of the in vivo effects of thyroid hormone on cardiac gene expression. Endocrinology. 1992; 130:2001-2006.
27. Danzi S, Ojamaa K, Klein I. Triiodothyronine-mediated myosin heavy chain gene transcription in the heart. Am J Physiol Heart Circ Physiol. 2003; 284:H2255-H2262.
28. Sanchez-Pacheco A, Aranda A. Binding of the thyroid hormone receptor to a negative element in the basal growth hormone promoter is associated with histone acetylation. J Biol Chem. 2003; 278:39383-39391.
29. Chopra IJ, Carlson HE, Solomon DH. Comparison of inhibitory effects of 3, 5, 3′-triiodothyronine (T3), thyroxine (T4), 3, 3, '5′- triiodothyronine (rT3), and 3, 3′-diiodothyronine (T2) on thyrotropin-releasing hormoneinduced release of thyrotropin in the rat in vitro. Endocrinology. 1978; 103:393- 402.
30. Ladenson PW, Sherman SI, Baughman KL, Ray PE, Feldman AM. Reversible alterations in myocardial gene expression in a young man with dilated cardiomyopathy and hypothyroidism. Proc Natl Acad Sci USA. 1992; 89:5251-5255.
31. Lowes BD, Gilbert EM, Abraham WT, Minobe WA, Larrabee P, Ferguson D, Wolfel EE, Lindenfeld J, Tsvetkova T, Robertson AD, Quaife RA, Bristow MR. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med. 2002; 346: 1357-1365.
32. Danzi S, Klein I. Thyroid hormone and the cardiovascular system. Minerva Endocrinol. 2004; 29:139 -150.
33. Tang YD, Kuzman JA, Said S, Anderson BE, Wang X, Gerdes AM. Low thyroid function leads to cardiac atrophy with chamber dilatation, impaired myocardial blood flow, loss of arterioles, and severe systolic dysfunction. Circulation. 2005; 112:3122-3130.
34. Wiersinga WM, Lie KI, Touber JL. Thyroid hormones in acute myocardial infarction. Clin Endocrinol (Oxf). 1981; 14:367-374.
35. Chowdhury D, Ojamaa K, Parnell VA, McMahon C, Sison CP, Klein I. A prospective randomized clinical study of thyroid hormone treatment after operations for complex congenital heart disease. J Thorac Cardiovasc Surg. 2001; 122:1023-1025.
36. Klemperer JD, Klein I, Gomez M, Helm RE, Ojamaa K, Thomas SJ, Isom OW, Krieger K. Thyroid hormone treatment after coronary-artery bypass surgery. N Engl J Med. 1995; 333:1522-1527.
37. Klemperer JD, Klein IL, Ojamaa K, Helm RE, Gomez M, Isom OW, Krieger KH. Triiodothyronine therapy lowers the incidence of atrial fibrillation after cardiac operations. Ann Thorac Surg. 1996; 61: 1323-1327; discussion 1328-1329.
38. Bennett-Guerrero E, Jimenez JL, White WD, D'Amico EB, Baldwin BI, Schwinn DA. Cardiovascular effects of intravenous triiodothyronine in patients undergoing coronary artery bypass graft surgery. A randomized, double-blind, placebo- controlled trial. Duke T3 study group. JAMA. 1996; 275:687- 692.
39. Brokhin M, Klein I. Low T3 syndrome in a patient with acute myocarditis. Clin Cornerstone. 2005; 7(Suppl 2):S28 -S29.
40. Olivares EL, Marassi MP, Fortunato RS, da Silva AC, Costa-e-Sousa RH, Araujo IG, Mattos EC, Masuda MO, Mulcahey MA, Huang SA, Bianco AC, Carvalho DP. Thyroid function disturbance and type 3 iodothyronine deiodinase induction after myocardial infarction in rats a time course study. Endocrinology. 2007; 148:4786-4792.
41. Yu J, Koenig RJ. Regulation of hepatocyte thyroxine 5′-deiodinase by T3 and nuclear receptor coactivators as a model of the sick euthyroid syndrome. J Biol Chem. 2000; 275:38296 -38301.
42. Simonides WS, Mulcahey MA, Redout EM, Muller A, Zuidwijk MJ, Visser TJ, Wassen FW, Crescenzi A, da-Silva WS, Harney J, Engel FB, Obregon MJ, Larsen PR, Bianco AC, Huang SA. Hypoxia-inducible factor induces local thyroid hormone inactivation during hypoxic-ischemic disease in rats. J Clin Invest. 2008; 118:975-983.
43. Wassen FW, Schiel AE, Kuiper GG, Kaptein E, Bakker O, Visser TJ, Simonides WS. Induction of thyroid hormone-degrading deiodinase in cardiac hypertrophy and failure. Endocrinology. 2002; 143:2812-2815.
44. Lee SH, Wolf PL, Escudero R, Deutsch R, Jamieson SW, Thistlethwaite PA. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. N Engl J Med. 2000; 342:626-633.
45. Kim CH, Cho YS, Chun YS, Park JW, Kim MS. Early expression of myocardial HIF-1alpha in response to mechanical stresses: regulation by stretch-activated channels and the phosphatidylinositol 3-kinase signaling pathway. Circ Res. 2002; 90:E25-E33.
46. Chen YF, Kobayashi S, Chen J, Redetzke RA, Said S, Liang Q, Gerdes AM. Short term triiodo-L-thyronine treatment inhibits cardiac myocyte apoptosis in border area after myocardial infarction in rats. J Mol Cell Cardiol. 2008; 44:180 -187.
47. Pantos C, Mourouzis I, Markakis K, Tsagoulis N, Panagiotou M, Cokkinos DV. Long-term thyroid hormone administration reshapes left ventricular chamber and improves cardiac function after myocardial infarction in rats. Basic Res Cardiol. 2008; 103:308 -318.
48. Lowes BD, Minobe W, Abraham WT, Rizeq MN, Bohlmeyer TJ, Quaife RA, Roden RL, Dutcher DL, Robertson AD, Voelkel NF, Badesch DB, Groves BM, Gilbert EM, Bristow MR. Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest. 1997; 100:2315-2324.